Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models
Open Access
- 5 December 2025
- journal article
- cancer
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (49) , eadx2984
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is generally resistant to conventional immunotherapies due to its immunosuppressive tumor microenvironment (TME). We combine an innate cell–enriched product activated by interleukin-2 (IL-2) and zoledronic acid (ZA) (ICP IL2ZA ) with low-dose radiotherapy (RT) and monoclonal antibodies (mAbs) to overcome this immunosuppressive TME. ICP IL2ZA is composed of natural killer (NK) cell– and monocyte-enriched immune cells, activated ex vivo with IL-2 and ZA. ICP IL2ZA with RT and mAbs promotes antibody-dependent cellular cytotoxicity and phagocytosis against PDAC. In murine models of PDAC, RT and mAb combined with ICP IL2ZA derived from either murine or healthy human donors controlled tumor growth. RT amplifies ICP IL2ZA effectiveness by inducing NKG2D ligands on tumor cells, facilitating immune infiltration that leads to tumor growth control and extends survival without apparent toxicity. These results suggest that ICP IL2ZA can overcome limitations of traditional therapies by augmenting antitumor capabilities of endogenous immune cells, highlighting a promising autologous strategy for PDAC and other immunologically “cold” tumors.Keywords
Funding Information
- National Institutes of Health (P30 CA014520)
- National Institutes of Health (NCI/NIH K08 CA285941)
- National Institutes of Health (NCI/NIH P01 CA250972)
- National Institutes of Health (NCI/NIH P01 CA250972)
- Midwest Athletes Against Childhood Cancer
- Midwest Athletes Against Childhood Cancer
- Midwest Athletes Against Childhood Cancer
- St. Baldrick’s Foundation Empowering Pediatric Immunotherapy for Childhood Cancers
- St. Baldrick’s Foundation Empowering Pediatric Immunotherapy for Childhood Cancers
- St. Baldrick’s Foundation Empowering Pediatric Immunotherapy for Childhood Cancers
This publication has 51 references indexed in Scilit:
- IL-2–dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cellsJournal of Experimental Medicine, 2013
- Natural killer (NK)–dendritic cell interactions generate MHC class II-dressed NK cells that regulate CD4+T cellsProceedings of the National Academy of Sciences, 2011
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and HumansScience, 2011
- Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 ImmunotherapyCancer Research, 2010
- Antigen presentation by monocytes and monocyte-derived cellsCurrent Opinion in Immunology, 2008
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006
- CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of CancerThe Journal of Immunology, 2006
- Reciprocal Activating Interaction between Natural Killer Cells and Dendritic CellsJournal of Experimental Medicine, 2002
- Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK CellsJournal of Experimental Medicine, 2002
- AUGMENTATION OF ANTIBODY DEPENDENT CELL-MEDIATED CYTOTOXICITY FOLLOWING INVIVO THERAPY WITH RECOMBINANT INTERLEUKIN-21990